North America Next-generation Sequencing (NGS) Market Report

To learn more about this report, Download Free Sample Report

North America Next-generation Sequencing (NGS) Market Size

The North America Next-generation Sequencing (NGS) market size was valued at USD 2.45 billion in 2026 and is estimated to reach USD 9.91 billion by 2034 from USD 2.86 billion in 2025, registering a CAGR of 16.81% from 2026 to 2034

The Next-generation Sequencing is the advanced technological systems for high throughput DNA and RNA sequencing that enables rapid and cost effective analysis of genetic material. This technology has revolutionized genomic research clinical diagnostics and personalized medicine by allowing scientists to sequence millions of DNA fragments simultaneously. The region serves as a global hub for NGS innovation driven by substantial investments in biotechnology robust healthcare infrastructure and supportive regulatory frameworks. As per the American Cancer Society, over 1.9 million new cancer cases are diagnosed annually in the United States, driving the adoption of NGS for tumor profiling and targeted therapy selection. The Food and Drug Administration has approved numerous NGS based tests for oncology and rare diseases establishing a clear pathway for clinical integration. Academic institutions and private laboratories continue to generate vast amounts of genomic data fostering an ecosystem of bioinformatics and data analytics.

MARKET DRIVERS

Rising Prevalence of Chronic Diseases and Cancer

The escalating burden of chronic diseases, particularly cancer serves is accelerating the growth of the North America Next-generation Sequencing (NGS) market. As per the American Cancer Society, approximately 1.9 million new cancer cases were projected to be diagnosed in the United States in 2023 with over 600000 deaths attributed to the disease. This high incidence rate necessitates precise diagnostic methods to identify specific genetic mutations and tailor treatment plans accordingly. NGS allows for comprehensive genomic profiling of tumors, enabling oncologists to select targeted therapies that improve patient outcomes and reduce adverse effects. The National Comprehensive Cancer Network guidelines increasingly recommend NGS based testing for various cancer types including lung breast and colorectal cancers. Additionally, the rising prevalence of cardiovascular diseases and diabetes drives interest in pharmacogenomics where NGS helps predict individual responses to medications. As per the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States accounting for 1 in every 5 deaths. Understanding genetic predispositions through NGS facilitates early intervention and personalized management strategies. This clinical utility ensures sustained demand for NGS platforms and reagents as healthcare providers seek to enhance diagnostic accuracy and therapeutic efficacy in managing complex chronic conditions.

Government Initiatives and Funding for Precision Medicine

The substantial government support and funding initiatives aimed at advancing precision medicine is significantly driving the growth of the North America Next-generation Sequencing market. As per the National Institutes of Health, the All of Us Research Program aims to gather data from one million or more people living in the United States to accelerate research breakthroughs and enable a new era of precision medicine. This massive undertaking relies heavily on NGS technologies to analyze genomic data alongside environmental and lifestyle factors. The Department of Veterans Affairs has also launched the Million Veteran Program which sequences the genomes of veterans to understand how genes affect health. These initiatives provide substantial financial resources for purchasing NGS instruments and developing analytical pipelines. Furthermore, the 21st Century Cures Act enacted by the US Congress facilitates the integration of real world evidence and genomic data into drug development processes. The Canadian Institutes of Health Research similarly supports genomic research through targeted funding programs focusing on rare diseases and personalized therapies.

MARKET RESTRAINTS

High Costs of Infrastructure and Data Storage

The significant financial burden associated with establishing and maintaining NGS infrastructure, particularly for smaller laboratories and healthcare facilities is degrading the growth of the North America next-generation sequencing market. The amount of data generated by genomic sequencing is growing exponentially with a single human genome producing approximately 200 gigabytes of raw data, according to the study. Storing and managing this vast volume of information requires robust IT infrastructure and cloud computing solutions, which incur substantial ongoing costs. The data storage expenses can account for up to 30% of the total cost of ownership for NGS operations. Additionally, the initial capital investment for high throughput sequencers ranges from hundreds of thousands to millions of dollars dependingon the platform capabilities. Smaller community hospitals and independent clinics often lack the financial resources to acquire such advanced equipment leading to disparities in access to genomic testing. Maintenance contracts and regular software updates further add to the operational expenses. These financial barriers limit the widespread adoption of NGS technologies in resource constrained settings. Consequently, many healthcare providers rely on reference laboratories for sequencing services, which may result in longer turnaround times and reduced control over data quality.

Shortage of Skilled Bioinformatics Professionals

The shortage of trained bioinformatics professionals capable of interpreting complex genomic data is also hindering the growth of the North America Next-generation Sequencing market. As per the American Medical Informatics Association, there is a growing gap between the volume of genomic data generated and the number of experts available to analyze it. NGS produces massive datasets that require sophisticated computational tools and statistical expertise to identify meaningful biological insights. However academic programs producing bioinformatics graduates have not kept pace with the rapid expansion of the genomics industry. Many laboratories struggle to recruit and retain qualified personnel leading to bottlenecks in data processing and reporting. This talent shortage delays the translation of sequencing results into clinical actionable information. Additionally, the complexity of NGS data interpretation requires continuous education and training, which adds to the operational burden. Without adequate human capital the potential of NGS technologies remains underutilized.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence in Genomic Analysis

The emergence of artificial intelligence and machine learning for enhancing data interpretation and diagnostic accuracy is solely attributed to bolster new opportunities for the growth of the North America next-generation sequencing market. AI algorithms can process vast genomic datasets more efficiently than traditional methods identifying patterns and variants that may be missed by human analysts. Machine learning models are increasingly used to predict the pathogenicity of genetic variants improving the reliability of clinical diagnoses. The Food and Drug Administration has begun to recognize AI based software as medical devices paving the way for regulatory approval of automated interpretation tools. Companies are developing platforms that integrate AI with NGS workflows to streamline variant calling and annotation processes. This automation reduces the time required for analysis from weeks to hours enabling faster clinical decision making. Additionally, AI enhances the discovery of novel biomarkers for drug development accelerating the creation of targeted therapies. The ability to handle complex multi omics data including genomics transcriptomics and proteomics further expands the utility of NGS.

Expansion into Non-invasive Prenatal Testing and Liquid Biopsies

The growing adoption of non-invasive prenatal testing and liquid biopsies by expanding its application beyond traditional tissue samples is also to accelerate the growth of the North America next-generation sequencing market. As per the American College of Obstetricians and Gynecologists, non-invasive prenatal testing using cell free fetal DNA in maternal blood has become a standard screening method for chromosomal abnormalities such as Down syndrome. NGS enables highly accurate detection of these anomalies without the risks associated with invasive procedures like amniocentesis. Similarly, liquid biopsies, which analyze circulating tumor DNA in blood samples are gaining traction for cancer monitoring and early detection. The National Cancer Institute supports research into liquid biopsies as a less invasive alternative to tissue biopsies for tracking tumor evolution and treatment response. These applications appeal to patients and clinicians due to their convenience and safety profile. NGS platforms are uniquely suited for detecting low frequency mutations in liquid samples requiring high sensitivity and specificity.

MARKET CHALLENGES

Complexity of Data Interpretation and Standardization

The inherent complexity of interpreting Next-generation Sequencing data and the lack of standardized protocols for consistent clinical implementation  is to decline the growth of the North America next-generation sequencing market. Variations in bioinformatics pipelines and reference databases can lead to discrepancies in variant identification and classification. Different laboratories may use distinct algorithms for aligning reads and calling variants resulting in inconsistent results for the same sample. This lack of harmonization complicates the comparison of data across studies and hinders the establishment of universal clinical guidelines. The Clinical Laboratory Improvement Amendments regulations require rigorous validation of laboratory developed tests but do not mandate standardized analytical methods. Consequently, clinicians may face uncertainty when interpreting reports from different providers. Additionally, the presence of variants of uncertain significance poses ethical and clinical dilemmas as their impact on health is often unknown. The American College of Medical Genetics and Genomics emphasizes the need for improved curation of variant databases to resolve these ambiguities.

Regulatory Uncertainty and Reimbursement Issues

The evolving regulatory landscape and securing adequate reimbursement for Next-generation Sequencing tests is also to limit the growth of the North America next generation sequencing market. As per the study, the regulatory oversight of laboratory developed tests, including NGS panels is subject to ongoing debate and policy changes creating uncertainty for manufacturers and laboratories. While some tests receive premarket approval, others operate under enforcement discretion leading to an uneven playing field. Additionally, reimbursement policies from Medicare and private insurers vary widely regarding coverage criteria and payment rates for NGS based diagnostics. The Centers for Medicare and Medicaid Services has implemented local coverage determinations that restrict reimbursement for certain genomic tests to specific indications limiting patient access. Many payers require extensive clinical utility evidence before approving coverage, which can be costly and time consuming to generate. The inconsistent reimbursement rates discourage investment in new test development. Laboratories often face delays in payment or denials due to coding complexities and lack of clear billing guidelines. These financial and regulatory hurdles increase the risk for companies entering the market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The services segment was accounted in holding a dominant share of the North America Next-generation Sequencing market in 2025. The growth of the services segment is driven by the widespread outsourcing of complex genomic workflows, including sample preparation sequencing and bioinformatics analysis. Many academic and clinical laboratories lack the specialized personnel and computational resources required to process terabytes of raw sequencing data efficiently. Consequently, they rely on contract research organizations and specialized service providers to ensure accurate and timely results. The clinical laboratories outsource at least part of their NGS testing to reference labs due to regulatory compliance and quality assurance requirements. These service providers offer end to end solutions that reduce the operational burden on hospitals and enable them to focus on patient care rather than technical logistics. Additionally, the rapid evolution of sequencing technologies necessitates continuous investment in equipment and training, which is often more cost effective when outsourced. Service providers leverage economies of scale to offer competitive pricing while maintaining high standards of accuracy. This trend is particularly pronounced in community hospitals, where capital constraints limit the acquisition of proprietary sequencing platforms.

The software segment is projected to register a fastest CAGR of 14.5% during the forecast period with the integration of artificial intelligence and machine learning algorithms into genomic analysis pipelines. The AI driven software tools can identify complex patterns in genomic data that traditional statistical methods may miss improving the accuracy of variant detection and disease prediction. These advanced algorithms automate the interpretation of variants of uncertain significance reducing the time required for clinical reporting from days to hours. The Food and Drug Administration has approved several AI based software applications for genomic analysis validating their clinical utility and safety. Companies are developing cloud based platforms that leverage machine learning to continuously improve their predictive models using real world data. This dynamic learning capability enhances the precision of diagnostics and personalized medicine applications. Additionally, AI software helps optimize experimental design by predicting the most informative sequencing strategies for specific research questions. The ability to handle multi omics data integration further expands the functionality of these software solutions.

By Technology Insights

The targeted re-sequencing segment was the largest by capturing 40.6% of the North America Next-generation Sequencing market share in 2025 due to its superior cost efficiency and high sensitivity in detecting known genetic variants associated with specific diseases. The targeted panels allow for deeper sequencing coverage of relevant genes compared to whole genome approaches enabling the detection of low frequency mutations in heterogeneous samples such as tumors. This depth is crucial for accurate diagnosis and monitoring of minimal residual disease in cancer patients. The National Comprehensive Cancer Network recommends targeted gene panels for guiding therapy selection in various cancers including lung and breast cancer due to their proven clinical utility. Additionally, targeted sequencing requires less data storage and computational power reducing the overall cost of analysis. The Centers for Medicare and Medicaid Services often provide clearer reimbursement pathways for targeted tests that have established clinical validity compared to broader sequencing methods. This financial predictability encourages hospitals and laboratories to adopt targeted panels for routine diagnostic workflows. Furthermore, the faster turnaround time of targeted assays meets the urgent needs of clinical decision making in acute care settings.

The whole genome sequencing segment is likely to grow at an anticipated CAGR of 12.8% during the forecast period owing to the dramatic decrease in sequencing costs which has made comprehensive genomic analysis economically viable for clinical applications. As per the study, the cost of sequencing a whole human genome has fallen below 1000 dollars removing a major barrier to widespread adoption. The Undiagnosed Diseases Network reports that WGS has a higher diagnostic yield for rare genetic disorders compared to exome sequencing particularly in cases where previous tests were inconclusive. This comprehensive nature reduces the need for sequential testing saving time and resources in the long run. The WGS can identify novel disease causing variants expanding the understanding of genetic etiologies. As insurance coverage for WGS expands due to its proven diagnostic value, more patients are gaining access to this powerful tool.

By Application Insights

The diagnostics application segment was the largest by holding 45.3% of the North America Next-generation Sequencing market share in 2025 with the routine integration of NGS based genomic testing into oncology care pathways for personalized treatment selection. Molecular profiling of tumors using NGS is now standard of care for many advanced cancers allowing clinicians to match patients with targeted therapies and immunotherapies. The guidelines mandate testing for specific genetic alterations in lung melanoma and colorectal cancers to determine eligibility for FDA approved drugs. This clinical necessity drives high volumes of diagnostic testing in hospitals and reference laboratories. The Food and Drug Administration has approved numerous companion diagnostic tests based on NGS technologies further validating their role in clinical decision making. Additionally, the rise of liquid biopsy diagnostics for monitoring treatment response and detecting resistance mutations contributes to sustained demand.

The personalized medicine application segment is likely to grow at a fastest CAGR of 13.2% during the forecast period with the advancements in pharmacogenomics which uses NGS to predict individual responses to medications. As per study, over 200 drug labels now include information about genetic biomarkers that influence efficacy and safety. NGS enables comprehensive profiling of pharmacogenes such as CYP450 enzymes allowing clinicians to adjust dosages or select alternative drugs to minimize adverse effects. The Clinical Pharmacogenetics Implementation Consortium provides guidelines for implementing pharmacogenomic testing in clinical practice promoting its adoption in hospitals. The Department of Veterans Affairs has implemented a nationwide pharmacogenomics program demonstrating the feasibility and benefits of preemptive genetic testing. This approach improves medication adherence and reduces healthcare costs associated with drug related complications. Patients and providers increasingly value the ability to tailor treatments based on genetic makeup rather than trial and error.

COUNTRY ANALYSIS

United States Next-generation Sequencing (NGS) Market Analysis

The United States was the top performer in the North America Next-generation Sequencing market by accounting for 85.3% of share in 2025 with its advanced healthcare infrastructure, robust biotechnology sector, and significant government funding. The country is home to major NGS instrument manufacturers and service providers fostering a vibrant ecosystem of innovation. As per the National Institutes of Health, the US invests billions of dollars annually in genomic research through programs like the All of Us Research Program. The presence of leading academic medical centers and private laboratories ensures widespread availability of NGS based diagnostics. The Food and Drug Administration provides a clear regulatory pathway for genomic tests encouraging commercial development. High prevalence of chronic diseases such as cancer drives clinical demand for precision diagnostics. Additionally, strong intellectual property protections attract global investment in genomics startups. However, high healthcare costs and reimbursement complexities remain challenges.

Canada Next-generation Sequencing (NGS) Market Analysis

Canada Next-generation Sequencing market was ranked second by holding 12.3% of share in 2025 with a publicly funded healthcare system and focused genomic initiatives. The country has a strong tradition of genomic research with institutions like the Ontario Institute for Cancer Research, leading in personalized medicine. The federal funding supports large scale genomic projects focusing on rare diseases and population health. The universal healthcare system facilitates equitable access to genomic testing although wait times can vary by province. Provincial governments are increasingly investing in genomic infrastructure to integrate sequencing into routine care. The Canadian Genomics Enterprise promotes collaboration between academia industry and government to accelerate commercialization. Collaboration with international partners helps overcome resource limitations. The focus on ethical considerations and data privacy shapes the regulatory landscape. These dynamics position Canada as a key player in responsible genomic innovation.

COMPETITIVE LANDSCAPE

The competition in the North America Next-generation Sequencing market is characterized by intense rivalry among established multinational corporations and emerging technology innovators vying for dominance in a rapidly evolving landscape. Major players compete primarily on sequencing speed accuracy cost efficiency and comprehensive bioinformatics support rather than price alone due to the high technical barriers to entry. Innovation in long read sequencing and single cell analysis serves as a key differentiator, as researchers seek deeper biological insights beyond standard genomic profiling. The market exhibits moderate consolidation with leading firms acquiring niche technology startups to expand their product portfolios and intellectual property holdings. Regulatory compliance and clinical validation are competitive factors. as healthcare providers prioritize approved and reliable diagnostic tools. Customer loyalty is driven by seamless integration with existing laboratory workflows and robust technical support services. However, the threat of new entrants with disruptive technologies remains constant prompting incumbents to continuously innovate.

KEY MARKET PLAYERS

Companies playing a leading role in the North America Next-generation Sequencing (NGS) Market include

• Illumina Incorporated
• Thermo Fisher Scientific
• Life Sciences (Roche)
• Pacific Biosciences
• Life Technologies Corp. (Thermo Fisher Scientific)
• Macrogen Inc.
• Partek Inc.
• Genomatix Software GmbH
• PerkinElmer Inc.
• GATC Biotech AG
• Agilent Technologies Inc.
• Biomatters Ltd.
• CLC Bio (Qiagen)
• BGI (Beijing Genomics Institute)
• Oxford Nanopore Technologies Ltd.
• DNASTAR Inc.
• Knome Inc.
• QIAGEN N.V.

Top Players in the Market

Illumina Inc

Illumina Inc maintains a dominant presence in the North America Next-generation Sequencing market, through its comprehensive portfolio of sequencing instruments and consumables. The company supplies high throughput platforms to academic institutions hospitals and commercial laboratories across the region. Illumina recently launched its NovaSeq X series, which significantly reduces the cost per genome and increases data output. This innovation strengthens its position by making large scale genomic studies more accessible to researchers. The company also expanded its cloud based bioinformatics solutions to streamline data analysis for clinical users. By integrating artificial intelligence into its software tools, Illumina enhances variant interpretation accuracy.

Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc contributes significantly to the North America NGS market by offering specialized targeted sequencing solutions and comprehensive laboratory support services. The company focuses on oncology and infectious disease applications providing validated panels that meet rigorous regulatory standards. Thermo Fisher, recently enhanced its Ion GeneStudio S5 system with improved sensitivity and faster turnaround times for clinical diagnostics. This upgrade addresses the growing demand for rapid and accurate pathogen identification in hospital settings. The company also expanded its network of reference laboratories to offer centralized testing services for complex genomic profiles. By combining robust hardware with expert bioinformatics support, Thermo Fisher ensures reliable results for clinicians.

Pacific Biosciences Corporation

Pacific Biosciences Corporation plays a vital role in the North America NGS market by providing long read sequencing technologies that resolve complex genomic regions. The company serves researchers studying structural variants and repetitive sequences that are difficult to analyze with short read methods. PacBio recently introduced its Revio system which offers higher throughput and lower costs for whole genome sequencing applications. This advancement makes long read technology more accessible for large scale population genomics projects. The company also partnered with leading academic centers to validate clinical applications for rare disease diagnosis. By demonstrating the unique value of long reads in solving undiagnosed cases PacBio expands its footprint in clinical genetics.

Top Strategies Used by the Key Market Participants

Key players in the North America Next-generation Sequencing market primarily employ product innovation and strategic partnerships to maintain competitive advantages. Companies invest heavily in research and development to reduce sequencing costs and improve data accuracy through advanced chemistries and optical systems. Strategic collaborations with pharmaceutical companies and academic institutions facilitate the integration of NGS into drug development and clinical trials. Manufacturers also focus on expanding their bioinformatics capabilities by acquiring software firms or developing proprietary algorithms for faster data interpretation. Regulatory compliance remains a priority as companies seek Food and Drug Administration approvals for diagnostic tests to broaden clinical adoption. Pricing strategies often involve bundled offerings of instruments and consumables to secure long term customer loyalty. Additionally, participants emphasize educational initiatives to train healthcare professionals on genomic data utilization.

MARKET SEGMENTATION

This research report on the North American next-generation Sequencing (NGS) Market has been segmented and sub-segmented into the following categories.

By Product 

• Software
• Services

By Technology 

• Targeted Re-Sequencing
• Whole Genome Sequencing
• De Novo Sequencing
• Exome Sequencing
• RNA-Seq
• ChIP-Seq
• Methyl-Seq

By Application 

• Diagnostics
• Drug Discovery
• Biomarker Discovery
• Personalized Medicine
• Agriculture
• Animals Research

By Country 

• The United States
• Canada
• Mexico
• Rest of North America